Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Jang, Na Young ^a,d   Kim, Dan Hyo ^b   Cho, Bong Jun ^b   Choi, Eun Jung ^b   Lee, Jong Soo ^c   Wu, Hong Gyun ^a   Chie, Eui Kyu ^a   Kim, In Ah ^a,b  

^a Seoul National University   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Ajou University   (South Korea)

^d Veterans Health Service Medical Center   (South Korea)

Author keywords

Olaparib; PARP inhibitor; PI 103; PI3K inhibitor; Radiotherapy; Triple negative breast cancer

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; BRCA1 PROTEIN; BRCA2 PROTEIN; DNA; ESTROGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; FURAN DERIVATIVE; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RADIOSENSITIZING AGENT;

ARTICLE; BIOLUMINESCENCE; BRAIN METASTASIS; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CELL DEATH; CELL SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; DISTANT METASTASIS; DNA STRAND BREAKAGE; DOUBLE STRANDED DNA BREAK; DOWN REGULATION; EXCISION REPAIR; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; IRRADIATION; LOCAL RECURRENCE FREE SURVIVAL; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; RADIOSENSITIZATION; REAL TIME POLYMERASE CHAIN REACTION; STEADY STATE; TRIPLE NEGATIVE BREAST CANCER; TUMOR XENOGRAFT; WESTERN BLOTTING; XENOGRAFT; ANIMAL; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; MOUSE; RADIATION RESPONSE; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRCA1 PROTEIN; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; FURANS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; PHTHALAZINES; PIPERAZINES; PYRIDINES; PYRIMIDINES; RADIATION-SENSITIZING AGENTS; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84924873608     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1090-7     Document Type: Article

References (28)

1. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429-34.
2. Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist. 2011;16 Suppl 1:1-11.
3. Pieper AA, Verma A, Zhang J, Snyder SH. Poly (ADP-ribose) polymerase, nitric oxide and cell death. Trends Pharmacol Sci. 1999;20:171-81.
4. Shall S, de Murcia G. Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat Res. 2000;460:1-15.
5. Ziegler M, Oei SL. A cellular survival switch: poly(ADP-ribosyl)ation stimulates DNA repair and silences transcription. BioEssays. 2001;23:543-8.
6. Dantzer F, Schreiber V, Niedergang C, Trucco C, Flatter E, De La Rubia G, et al. Involvement of poly(ADP-ribose) polymerase in base excision repair. Biochimie. 1999;81:69-75.
7. Fortini P, Pascucci B, Parlanti E, D'Errico M, Simonelli V, Dogliotti E. The base excision repair: mechanisms and its relevance for cancer susceptibility. Biochimie. 2003;85:1053-71.
8. Tucker CL, Fields S. Lethal combinations. Nat Genet. 2003;35:204-5.
9. Comen EA, Robson M. Inhibition of poly(ADP)-ribose polymerase as a therapeutic strategy for breast cancer. Oncology. 2010;24:55-62.
10. Gage M, Wattendorf D, Henry LR. Translational advances regarding hereditary breast cancer syndromes. J Surg Oncol. 2012;105:444-51.
11. Anders CK, Winer EP, Ford JM, Dent R, Silver DP, Sledge GW, et al. Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. Clin Cancer Res. 2010;16:4702-10.
12. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer. 2004;4:814-9.
13. Gelmon KA, Hirte HW, Robidoux A, Tonkin KS, Tischkowitz M, Swenerton K, et al. Can we define tumors that will respond to PARP inhibitors- A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer. J Clin Oncol. 2010;28:abstr 3002.
14. Kumar A, Fernandez-Capetillo O, Carrera AC. Nuclear phosphoinositide 3-kinase beta controls double-strand break DNA repair. Proc Natl Acad Sci U S A. 2010;107:7491-6.
15. Ibrahim YH, Garcia-Garcia C, Serra V, He L, Torres-Lockhart K, Prat A, et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discovery. 2012;2:1036-47.
16. Chalmers AJ, Lakshman M, Chan N, Bristow RG. Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. Semin Radiat Oncol. 2010;20:274-81.
17. Kim IA, Shin JH, Kim IH, Kim JH, Kim JS, Wu HG, et al. Histone deacetylase inhibitor-mediated radiosensitization of human cancer cells: class differences and the potential influence of p53. Clin Cancer Res. 2006;12:940-9.
18. Choi EJ, Ryu YK, Kim SY, Wu HG, Kim JS, Kim IH, et al. Targeting epidermal growth factor receptor-associated signaling pathways in non-small cell lung cancer cells: implication in radiation response. Mol Cancer Res. 2010;8:1027-36.
19. Senra JM, Telfer BA, Cherry KE, McCrudden CM, Hirst DG, O'Connor MJ, et al. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. Mol Cancer Ther. 2011;10:1949-58.
20. Elias L, Crissman HA. Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites. Cancer Res. 1988;48:4868-73.
21. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell. 2011;19:58-71.
22. Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandarlapaty S, et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene. 2011;30:2547-57.
23. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28:3271-7.
24. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010;28:1684-91.
25. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376:235-44.
26. Jackson SP. Sensing and repairing DNA double-strand breaks. Carcinogenesis. 2002;23:687-96.
27. Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balmana J, et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discovery. 2012;2:1048-63.
28. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26:3279-90.